A Phase 3 Study of AZD0901 Versus Standard Therapy to Treat Advanced Stomach or Gastroesophageal Junction Cancer With Claudin18.2

Full Title

A Phase III Multi-center, Open-label, Sponsor-blinded, Randomized Study of AZD0901 Monotherapy Compared with Investigator’s Choice of Therapy in Second- or Later-Line Adult Participants with Advanced/Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma Expressing Claudin18.2 (CLARITY-Gastric 01) (WIRB)

Purpose

Researchers are comparing AZD0901 with standard treatments in people with advanced gastric cancer. The people in this study have cancer of the stomach or the junction between the esophagus and stomach (gastroesophageal junction). The people in this study have cancers that make a protein called Claudin18.2 (CLDN18.2).

If you join this study, you will be randomly assigned to get one of these treatments:

• AZD0901 alone
• A standard therapy for your cancer, such as ramucirumab, paclitaxel, docetaxel, irinotecan, or TAS-102.

Contact

For more information or to see if you can join this study, please call Dr. Yelena Janjigian’s office at 646-888-4286.